AI drug developer Chai Discovery closed a $130 million Series B at a $1.3 billion valuation to expand its computational platform and molecule generation efforts. The company highlighted Chai 2, its next‑generation design model, and said the financing will accelerate antibody-design programs and early preclinical work with pharma partners. Investors include Oak HC/FT, General Catalyst and existing backers.